Printer Friendly
The Free Library
5,671,890 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Research and Markets : Psoriasis - Biologics Impact Treatment Regimes Across The Globe.


DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c19816) has announced the addition of Psoriasis psoriasis (sôrī`əsĭs), occasionally acute but usually chronic and recurrent inflammation of the skin. The exact cause is unknown, but the disease appears to be an inherited, possibly autoimmune disorder that causes the  - Biologics Impact Treatment Regimes Across The Globe to their offering

Psoriasis is a non-life threatening but highly debilitating de·bil·i·tat·ing
adj.
Causing a loss of strength or energy.


Debilitating
Weakening, or reducing the strength of.

Mentioned in: Stress Reduction
 disease that currently has no cure. Traditional treatments often either lack efficacy or are effective but have very poor side-effect profiles, limiting them to use in severe disease only. However, the market is growing as disease awareness increases through the approval and marketing of novel biologic treatments in this indication.

Report Scope

- Overview of disease including detailed epidemiology epidemiology, field of medicine concerned with the study of epidemics, outbreaks of disease that affect large numbers of people. Epidemiologists, using sophisticated statistical analyses, field investigations, and complex laboratory techniques, investigate the cause , physician estimated diagnosis rates and severity split

- Breakdown of treatment trends in the following markets: US, Japan, France, Germany, Italy, Spain and the UK

- Survey of PCPs and dermatologists in the major markets to capture the treatment of the ranging severities of psoriasis, from mild to severe patients

- Review of current treatment options and clinical debate including comments from key opinion leaders

Report Highlights

- Psoriasis is currently under diagnosed with an average of 55% of sufferers diagnosed by a physician. However, awareness of the debilitating nature of this disease is increasing, driven by the introduction of high profile biologic brands into the market.

- Topical topical /top·i·cal/ (top´i-k'l) pertaining to a particular area, as a topical antiinfective applied to a certain area of the skin and affecting only the area to which it is applied.

top·i·cal
adj.
 treatments such as calcipotriol and corticosteroids Corticosteroids Definition

Corticosteroids are group of natural and synthetic analogues of the hormones secreted by the hypothalamic-anterior pituitary-adrenocortical (HPA) axis, more commonly referred to as the pituitary gland.
 still dominate psoriasis treatment, leaving a gap for the moderate severity patient not effectively treated by this group, but not severe enough for an expensive or toxic systemic treatment.

- Current and pipeline biologic brands are differentiated from selected traditional brands by their perceived superior efficacy, side-effect profile, dosing frequency and ability to treat comorbidities.

Reasons to Purchase

- Differentiate your product in the crowded psoriasis market through an understanding of physician perceptions of key product brands

- Identify unmet un·met  
adj.
Not satisfied or fulfilled: unmet demands. 
 needs and the most important attributes to prescribing physicians for steroidal steroidal

emanating from or pertaining to steroid.


steroidal saponins
see lithogenic saponins.

steroidal (Solanum spp.
, biologic and vitamin derivative treatment classes

- Forecast product usage across the seven major markets based on estimated treatment class patient numbers

For more information visit http://www.researchandmarkets.com/reports/c19816
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
psoriasis89
john smith (Member): Psoriasis? 6/27/2009 11:32 AM
What is psoriasis? What causes psoriasis? Is there a cure or treatment for psoriasis? Psoriasis is a skin condition, it is a disease, but it is not contagious. The name comes from the Greek word for "itch." It can be hereditary, caused by external influences (allergic reaction to foods or the environment) and sometimes stress. 4-5% of the population is known to be affected, and this number is growing. However, it is suspected that 1 in 5 people have some form of psoriasis either descripts or none descript.<br>Once you have psoriasis, it is very likely you will have it for ever. It may go away, and come back. It might respond to various treatments, and it may not. Basically psoriasis is your body over producing skin cells. You have too many skin cells in one location which is why it often swells up, becomes dry and even flaky. It can often be very itchy, red, sore, cracked and very tender. Psoriasis usually affect the scalp, hands, stomach, knees, feet and elbows. It is linked to dandruff and unfortunately to some forms of arthritis. <br>http://www.superherbalcare.com<br>

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 24, 2005
Words:322
Previous Article:Winners of Ernst & Young Entrepreneur Of The Year Awards Announced in New England.
Next Article:PPG Industries, Inc. Announces Completion of Its EUR 300 Million International Debt Offering.



Related Articles
Double trouble: risks of psoriasis therapy.
Q&A : ADVICE FROM EXPERTS UNDERSTANDING SYMPTOMS, COURSE OF PSORIASIS.(L.A. LIFE)
Injections counteract psoriasis in patients. (Clear Skin).
AMGEN TOUTING ENBREL'S EVERY STEP.(Business)
Women & skin health.
Increased Diagnosis Spur U.S. Autoimmune Disorders Markets for Biologics.
FDA Accepts Application Requesting Approval of REMICADE in the Treatment of Psoriatic Arthritis.
UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III STUDIES.
Research and Markets: Enbrel has Paved the Way for Anti-TNF Therapies to Launch Directly in Psoriasis.
UCB INITIATES ADDITIONAL SHORT-TERM CLINICAL STUDY OF CIMZIA.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles